Back To Top
Chong Kun Dang signs licensing deal with Synaffix to develop ADCs
Chong Kun Dang signs licensing deal with Synaffix to develop ADCs
TechnologyFeb 6, 2023
Korean pharmaceutical firm Chong Kun Dang said Monday that it signed a licensing deal with Dutch company Synaffix to gain access to the latter's technologies needed to develop new antibody drug conjugates. The size of the deal, which was inked Friday, is estimated at around $132 million, plus tiered royalties on commercial sales in the future. “The company will speed up development of next-generation anti-cancer treatment through the latest deal with Synaffix,” said Chong Kun Da